Industry Insights

  1. Why Invest In Emerging Markets Now

    Unexplored and emerging markets are an attractive prospect for biopharma companies looking to expand. But when it comes to ensuring success, what’s the wisest way to invest?

  2. Industry 4.0: Embracing Digital Transformation In Bioprocessing

    Currently, there is a transformation taking place that will pave the way for even more changes to how the industry approaches drug manufacturing.

  3. Choosing The Right Single-Use Bioreactor Platform

    When selecting a bioreactor, It is important that this core technology is carefully chosen, specified, designed, and supported, both now and in the future.

  4. Solving The OOS Problem With Continuous Manufacturing

    With continuous manufacturing, it is possible to monitor product quality continuously, and make adjustments in real time to keep the product in spec.

  5. The Upswing Of Sterile Injectables

    The $330 bn global sterile market is expected to reach $525 bn by 2020, growing at a CAGR of 11% -with North America contributing 48% while APAC is expected to record highest CAGR of 13%.

  6. Top 5 Events That Can Impact Your Clinical Supply Chain

    Review practical solutions for “small changes” in the clinical supply chain that can wreak havoc if not planned for in advance.

  7. Biopharma’s Talent Crunch: How To Gain And Retain Skilled Labor In A Growing Industry

    What strategies should your company consider for recruiting, training, and retaining qualified candidates in order to remain competitive in a burgeoning biopharma market?

  8. What Value Does An Integrated CDMO Bring To Your Outsourcing Strategy?

    Should a sponsor companies seek the traditional route of utilizing multiple partners across the supply chain or does an integrated CDMO offer a more efficient and faster path to commercialization?

  9. An Approach To Tech Transfer For Early Phase GMP Manufacturing

    Biotech firms often have tight timelines to prove the concept of their NCE. As a result, modern clinical development pathway requires rapid manufacturing of the “first Kilo”.

  10. Characterizing Novel Microparticle-Encapsulated Drug Formulations

    Once you have successfully encapsulated an (API), the next task is to characterize that product and understand its release kinetics, such that it can be labeled and prepared for subsequent studies. Following are some lessons learned from characterizing the end product.